MedTrace Logo

PSMA PET and MRI in Gynecological Cancers

NCT03302156 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-09-05

Study results available
· View outcomes & findings →

Summary

The goal of this research is to determine the accuracy of PSMA positron emission tomography (PET) and multi-parametric magnetic resonance (MR) imaging to detect the presence of gynecological cancer cells in the body.

Conditions

  • Gynecologic Cancer

Interventions

DRUG

PSMA-based 18F-DCFPyL PET tracer

PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Steve Cho, MD · University of Wisconsin, Madison

  • Elizabeth Sadowski, MD · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2020-01-20
Completion
2020-01-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03302156 on ClinicalTrials.gov